Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Conditions:   Advanced Malignancies;   Metastatic Malignancies
Interventions:   Drug: INCAGN01876;   Drug: Nivolumab;   Drug: Ipilimumab
Sponsor:   Incyte Corporation
Recruiting - verified April 2017

http://ift.tt/2pWOJmu